Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial

@article{Moretti2018CombinedOC,
  title={Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial},
  author={Costanzo G Moretti and Laura Guccione and Paola Di Giacinto and Ilaria Simonelli and Caterina Exacoustos and Vincenzo Toscano and Cecilia Motta and Vincenzo de Leo and Felice Petraglia and Andrea Lenzi},
  journal={The Journal of Clinical Endocrinology \& Metabolism},
  year={2018},
  volume={103},
  pages={824–838}
}
Context Hirsutism often occurs in women with polycystic ovary syndrome (PCOS). The efficacy of oral contraceptive pill (OCP) plus antiandrogens in the treatment of its severe expression is controversial due to the lack of randomized, double-blind, long-term studies. Objective The primary outcome was the reduction of hirsutism in PCOS women objectively measured by videodermoscopy on the androgen-sensitive skin areas assessed by the modified Ferriman and Gallwey (mF&G) total score, after 12… 

Figures and Tables from this paper

A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy

There is no solid evidence supporting that the use of combined oral contraceptives in women with PCOS increases the risk of cardiovascular or thromboembolic events compared with the general population.

Oral bicalutamide for female pattern hair loss: A pilot study

Antiandrogen therapy with flutamide was useful for the treatment of FPHL with a mean improvement in Ludwig scores about 15 to 28% in 6 to 24 months, although adverse effects limited this therapy.

A Summary on Polycystic Ovary Syndrome: Diagnostic Criteria, Prevalence, Clinical Manifestations, and Management According to the Latest International Guidelines.

This review covers diagnostic criteria, prevalence, phenotypes, reproductive, metabolic, and psychological factors of PCOS, and management strategies including lifestyle interventions as well as treatment of nonreproductive outcomes and reproductive outcomes informed by the latest international evidence-based guidelines.

Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know

Although future prospective, comparative, randomized clinical trials are essential to establish the ideal dose and efficacy of the drug, oral bicalutamide appears to be a promising option to expand the arsenal of FPHL treatment.

Diagnostic values of MRI indexes for polycystic ovary syndrome.

BACKGROUND Magnetic resonance imaging (MRI) is a useful non-invasive modality for observation of ovarian morphologic characteristics. Few studies have focused on the value of MRI-derived indexes in

A systematic review of antiandrogens and feminization in transgender women

It is unclear whether spironolactone's antagonism of the androgen receptor results in clinically meaningful differences in feminization, and further research with clinically meaningful endpoints is needed to optimize the use of antiandrogens in transgender women.

Update on PCOS: Consequences, Challenges and Guiding Treatment.

The review highlights some of the remaining challenges in the understanding and management of PCOS to help guide clinicians and investigators in this perplexing condition.

The Role of Probiotics and Synbiotics on Hirsutism

The increasing interest on insulin resistance and synbiotics indicate a potential beneficial effect on hirsutism through the management of insulin resistance.

Management of cardiometabolic complications in polycystic ovary syndrome: Unmet needs

  • Licy L. Yanes CardozoD. Romero
  • Medicine, Biology
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2021
A perspective manuscript aims to highlight the unmet need for effective and safe management of the cardiometabolic complications in PCOS patients.

References

SHOWING 1-10 OF 70 REFERENCES

Management of Hirsutism

This review reports its own experience with, and literature studies of, the pharmacological management of hirsutism in women with hyperandrogenism or with normal serum androgen levels and regular ovulatory menstrual cycles.

Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.

The effectiveness of treatment for either acne vulgaris or hirsutism cannot be determined due to the small sample populations involved in the trials and its value in clinical practice is difficult to assess from currently available research.

New alternative treatment in hirsutism: bicalutamide 25 mg/day

Bicalutamide at 25 mg/day is an effective drug in the treatment of patients with hirsutism and clinical improvement in the degree of hirsUTism was observed in all patients by the same author.

Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments

Lifestyle interventions reduced body mass index but did not show improvement in hirsutism, and although cosmetic measures are frequently used, no RCTs investigating cosmetic treatments were identified.

Modified Ferriman-Gallwey hirsutism score and androgen levels in Turkish women.

Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome.

There are different phenotypes of women with hirsutism and PCOS that may require specific attention in the choice of treatment, and when obesity is present, lifestyle intervention should be always considered, and if necessary combined with pharmacotherapy.

Treatment of hirsutism in women with flutamide.

Flutamide favorably influenced hirsutism in women, with differences noted after only 3 months of therapy, and more prolonged and detailed studies of this drug as the sole therapeutic agent for treatment of hirsUTism seems warranted.
...